BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30520145)

  • 1. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
    Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
    J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
    [No Abstract]   [Full Text] [Related]  

  • 3. The Good and Bad News About New Drugs for Treating Alopecia Areata.
    Morgado-Carrasco D; Rodríguez-Lobato E; Riera-Monroig J; Ferrando J
    Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
    [No Abstract]   [Full Text] [Related]  

  • 4. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 7. Topical tofacitinib in treatment of alopecia areata.
    Ferreira SB; Ferreira RB; Scheinberg MA
    Einstein (Sao Paulo); 2020; 18():eAI5452. PubMed ID: 32785452
    [No Abstract]   [Full Text] [Related]  

  • 8. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 10. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for the treatment of severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
    [No Abstract]   [Full Text] [Related]  

  • 18. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's New in Hair Loss.
    Santos LDN; Shapiro J
    Dermatol Clin; 2019 Apr; 37(2):137-141. PubMed ID: 30850035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK Inhibitors for the Treatment of Pediatric Alopecia Areata.
    Hamilton CE; Craiglow BG
    J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S31-S36. PubMed ID: 33099381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.